Organon stock reaches new 52-week high at USD 13.83

Organon stock reached a new 52-week high of USD 13.83 during trading on October 29, 2026, according to Investing.com. The report said the stock had advanced substantially over the preceding year, but it did not attribute the move to a specific new corporate announcement.

Pending transaction remains central

Organon is expected to file its third-quarter 2026 results in the company's regularly scheduled Form 10-Q filing. Its investor-relations page lists the filing plan and identifies the company as traded on the New York Stock Exchange under ticker OGN.

The proposed acquisition by Sun Pharmaceutical Industries remains an important part of the investment context. The transaction could make the upcoming filing one of Organon's last reports as an independent company, subject to the required approvals and closing conditions.

Euro quote lacks Xetra comparison

The latest Lang & Schwarz snapshot showed Organon at EUR 12.33 on October 29, 2026, at 23:00 Berlin time, with a bid of EUR 12.28 and an ask of EUR 12.38. A directly comparable Xetra closing price was not available for this report, so no Xetra-based daily percentage change is stated.

Readers can follow the real-time quote of Organon stock. The USD high reported by Investing.com and the euro-denominated Lang & Schwarz quote refer to different trading venues and currencies and should not be treated as a direct price comparison.

The broader US equity market provides the relevant market backdrop for Organon as a US-listed company: current market developments in the S&P 500 may influence the setting for US-listed healthcare shares.

For further company-specific coverage, see more news and analyses on Organon stock.